FWIW
If you know them personally.
Mikhail V. Blagosklonny
David M. Sabatini
Nir Barzila
Matt Kaeberlein
Joan Mannick
6 Likes
Matt kaeberlein us already a member, but doesnāt visit often and has a lot going on. His social media preferences are Twitter but with his phasing out of academia seems to be less active there.
2 Likes
Agetron
#4
After signing up for the University of Washington Survey on Rapamycin, I think Tammi Kaeberlein or Matt recommended I come to this site. Someone did.
That is how I got here.
Excellent suggestion.
2 Likes
Kaeberlein is phasing out academia? how do you know?
Wow, so many people have been lately. Many of them with minimal teaching loads too.
1 Like
Matts been talking about it for the past year in private, but with the announcements of Oral Biomedical, and then OptiSpan Ventures, I think heās been more open about it.
I think he believes he can move the field forward faster now outside academia than inside.
1 Like
I know that one of our members did a ācoldā email to Sabatini asking questions and never got a response.
Nir is very focused on Metformin and is generally extremely cautious when it comes to rapamycin, so doubt heād be too interested.
And Joan Mannick is of course leader of Tornado Therapeutics developing a ācompetitorā to rapamycin, and has said that she doesnāt take rapamycin (see the bottom of list of āwho in the Health and Longevity Field is taking rapamycinā thread).
1 Like
What happened to restorbio???
It shut down when their phase 3 clinical trial didnāt meet the end points (the FDA changed the endpoints between the phase 2 clinical study where it was successful, and the phase 3 trial).
2 Likes
